Latest / Glaucoma, Vision & Longevity: Supplements & Science / Home Tonometers and Contact Lens Sensors in April 2026 Protocols

Transcript

Home Tonometers and Contact Lens Sensors in April 2026 Protocols · Glaucoma, Vision & Longevity: Supplements & Science

• 0:00
  SPEAKER_00: Introduction.
• 0:00
  SPEAKER_00: Glaucoma management is evolving with home-based intraocular pressure, IOP monitoring.
• 0:06
  SPEAKER_00: Traditionally, eye pressure is checked only during office visits, but new devices let patients measure IOP at home or wear sensors in their eyes.
• 0:15
  SPEAKER_00: In fact, by 2026, several clinical trials began incorporating these technologies.
• 0:20
  SPEAKER_00: Home tenometers, like the FDA-approved eye care home rebound tenometer, allow patients to check their own IOP without anesthesia.
• 0:29
  SPEAKER_00: Smart contact lenses equipped with sensors, e.g., the Sensimed Triggerfish CLS, can continuously record 24-hour pressure patterns.
• 0:38
  SPEAKER_00: These trials explore how such data can improve efficacy outcomes and trigger safety interventions, while ensuring data quality and patient comfort.
• 0:48
  SPEAKER_00: Trials with home IOP monitoring, several recent and upcoming trials starting around April 2026, include home telometry in their protocols.
• 0:56
  SPEAKER_00: For example, an academic study at Willseye Hospital is testing home monitoring for mild to moderate glaucoma patients.
• 1:04
  SPEAKER_00: Participants use the eye care home telometer at home, measuring IOP multiple times and uploading data alongside a portable perimeter for visual field testing.
• 1:13
  SPEAKER_00: Similarly, a large Guangdong Hong Kong trial randomizes newly diagnosed glaucoma patients to one home telemonitoring with eye care home plus a smartphone coaching program, or two, standard care with smartphone support.
• 1:27
  SPEAKER_00: In that trial, patients in the home monitoring arm upload six IOP readings weekly, two days per week, thrice daily, to a secure cloud platform, eye Care Clinic.
• 1:37
  SPEAKER_00: Another diurnal monitoring trial in Switzerland, NCT 04485897, compares 24-hour hospital-based IOP monitoring to patient self-tonometry at home.
• 1:48
  SPEAKER_00: In that study, patients use the eye care device on themselves, and investigators analyze how well the home pressure curve matches the clinic curve.
• 1:57
  SPEAKER_00: These and other trials explicitly incorporate home IOP data into their endpoints and decision rules.
• 2:03
  SPEAKER_00: Trials with continuous contact lens sensing.
• 2:06
  SPEAKER_00: A parallel line of research uses smart contact lenses to measure IOP continuously.
• 2:12
  SPEAKER_00: For example, the MonBH Barcelona ISRCTN 6540132 trial is studying glaucoma patients who undergo minimally invasive eye stent surgery.
• 2:23
  SPEAKER_00: Both the surgery group and a control group get 24-hour monitoring with the Sensimed Triggerfish contact lens sensor at baseline and follow-up, e.g., one or three months later.
• 2:32
  SPEAKER_00: The triggerfish is a soft silicone lens, 14.1 mm diameter, 585 mm thick, embedded with microstrain gauges, a chip, and an antenna.
• 2:43
  SPEAKER_00: It transmits pressure-related data to an adhesive orbital antenna and portable recorder worn by the patient.
• 2:49
  SPEAKER_00: Such trials use the sensor output to quantify circadian IOP patterns.
• 2:54
  SPEAKER_00: For instance, the Spanish eye stent trial defines the primary outcome as the amplitude of a fitted 24-hour IOP curve derived from the lens data.
• 3:04
  SPEAKER_00: In short, modern protocols combine traditional endpoints, like average IOP or nerve fiber thinning, with novel continuous IOP measurements from these contact lenses.
• 3:14
  SPEAKER_00: Device specifications and calibration.
• 3:17
  SPEAKER_00: Home tonometers such as the eye care home are rebound tonometers.
• 3:20
  SPEAKER_00: A lightweight handheld probe gently bounces a small disposable tip off the cornea to compute pressure.
• 3:26
  SPEAKER_00: The eye care home, model TA022, was FDA cleared in 2017 and comes with disposable tips, 40mm probes that eliminate the need for anesthesia.
• 3:38
  SPEAKER_00: Rebound tenometers do not require regular calibration like some other tonometers.
• 3:43
  SPEAKER_00: Patient training is needed, however.
• 3:46
  SPEAKER_00: Before using the device independently, each patient is certified by a trained professional.
• 3:53
  SPEAKER_00: Training includes learning to position the device and support it against the cheek and forehead, which are measured and recorded for consistency.
• 4:00
  SPEAKER_00: Only after meeting the manufacturer's accuracy criteria, e.g., taking consistent triplicate readings, can a patient use the device routinely.
• 4:10
  SPEAKER_00: Contact lens sensors like the triggerfish are one size fits all, with a few base curves and require no patient calibration.
• 4:17
  SPEAKER_00: An eye doctor fits the lens at the clinic for a 24-hour recording session.
• 4:22
  SPEAKER_00: The device itself, a soft hydrogel lens, contains strain gauges and electronics.
• 4:28
  SPEAKER_00: When pressure or ocular expansion changes the lens curvature, the strain gauges detect it and send data via the external antenna.
• 4:35
  SPEAKER_00: Because these sensors output a relative signal, not a direct Memet Hergdrime reading, protocols often calibrate each session by fitting models, like a 24H cosigner, to the recorded waveform instead of matching Goldman measurements.
• 4:49
  SPEAKER_00: In some, home tonometers need a one-time patient certification and have built-in stability, no ongoing calibration.
• 4:57
  SPEAKER_00: Contact lenses require skilled fitting but minimal patient effort during wear.
• 5:02
  SPEAKER_00: Patient training and adherence support studies invest heavily in training and reminders to ensure accurate use.
• 5:09
  SPEAKER_00: In the eye care home trials, patients must demonstrate proficiency at an initial visit.
• 5:15
  SPEAKER_00: After training, trials often employ digital tools to encourage compliance.
• 5:19
  SPEAKER_00: In the Hong Kong trial, for instance, patients receive automated text messages via a smartphone app.
• 5:25
  SPEAKER_00: Every four weeks, they get messages telling them whether their IOP readings have met target goals and reminders to take medications, and the patients reply via text to confirm adherence.
• 5:37
  SPEAKER_00: Similarly, home tonometer data are uploaded automatically to an online portal, e.g.
• 5:42
  SPEAKER_00: eye care clinic, letting clinicians track if measurements are missed.
• 5:47
  SPEAKER_00: For contact lenses, adherence simply means wearing the device for the required period.
• 5:52
  SPEAKER_00: Researchers typically supervise insertion and ask patients to note any errors or remove the lens early.
• 5:59
  SPEAKER_00: In all cases, clear protocols and digital reminders help maintain high adherence to scheduled self-monitoring.
• 6:06
  SPEAKER_00: Integrating home data into endpoints and safety triggers.
• 6:10
  SPEAKER_00: Home collected IOP data can strengthen efficacy assessments.
• 6:13
  SPEAKER_00: For example, one trial treats the clinic-measured IOP over time via Goldman applination telonometry as the primary outcome, but uses home telometry to guide therapy.
• 6:23
  SPEAKER_00: The Hong Kong trial hypothesizes that having frequent home IOP readings will lower mean IOP and slow nerve fiber loss compared to standard care.
• 6:32
  SPEAKER_00: In analysis, they plan to correlate the home derived metrics, like mean IOP and IOP fluctuations, with structural outcomes, RNFL thinning.
• 6:41
  SPEAKER_00: In another study, home self-tonometry is directly compared to 24H in hospital profiles.
• 6:48
  SPEAKER_00: The primary endpoint is simply the agreement between the two IOP patterns, and continuous lens data can be turned into summary endpoints, e.g., the Barcelona trial uses the fitted amplitude of the 24H IOP curve from the CLS data as its main outcome.
• 7:04
  SPEAKER_00: Home readings can also serve as early safety signals.
• 7:07
  SPEAKER_00: Protocols typically pre-specify pressure thresholds or warning rules.
• 7:12
  SPEAKER_00: For instance, the majority of trials set rules like if home IOP readings consistently exceed the treatment goal by a large margin, study staff intervene.
• 7:21
  SPEAKER_00: In the Hong Kong trial, participants were withdrawn if they met safety criteria, such as two consecutive visits with IOP 35mm Hergrax.
• 7:30
  SPEAKER_00: Likewise, the Swiss diurnal monitoring study includes a secondary outcome of treatment changes triggered by IOP peaks, meaning any detected spike, at home or in hospital, prompts a medication change.
• 7:43
  SPEAKER_00: In practice, trial teams review uploads and will call patients if a reading is dangerously high.
• 7:48
  SPEAKER_00: Thus, home data feed directly into efficacy endpoints by providing a fuller IOP profile and into safety triggers by alerting clinicians to out-of-range pressures.
• 7:59
  SPEAKER_00: Data quality assurance and patient burden.
• 8:02
  SPEAKER_00: Ensuring reliable home data is crucial.
• 8:05
  SPEAKER_00: Devices often take repeated measurements and average them.
• 8:08
  SPEAKER_00: For example, the eye care home's readings are based on multiple probe contacts to smooth out error.
• 8:14
  SPEAKER_00: Some trials exclude patients who cannot meet quality criteria.
• 8:18
  SPEAKER_00: One Hong Kong study disqualified anyone who failed the eye care certification at baseline.
• 8:24
  SPEAKER_00: Others compare a subset of home readings to technician measurements to check accuracy.
• 8:29
  SPEAKER_00: Despite these checks, home measurements tend to be slightly noisier.
• 8:32
  SPEAKER_00: Studies report small average biases, e.g., a 1 mm gram underestimation of true IOP and wider spread than clinic telometry.
• 8:42
  SPEAKER_00: From the patient's viewpoint, home monitoring adds tasks.
• 8:45
  SPEAKER_00: Most eye care home telometry studies instruct patients to measure IOP several times daily or weekly.
• 8:51
  SPEAKER_00: For example, one protocol required thrice daily measurements for a week every quarter.
• 8:56
  SPEAKER_00: These routines impose time and skill demands.
• 8:59
  SPEAKER_00: Fortunately, training seems effective.
• 9:02
  SPEAKER_00: A recent review found that about 82.5% of patients could successfully learn self-tonometry.
• 9:08
  SPEAKER_00: Most participants report the device is easy, median 72% found it easy to use and comfortable,.92% found wear acceptable.
• 9:17
  SPEAKER_00: Learning typically took under 20 minutes, and patients often felt confident at home.
• 9:23
  SPEAKER_00: Contact lens sensors carry a different kind of burden.
• 9:26
  SPEAKER_00: Patients must wear a tight-fitting lens for a full day, which usually causes mild irritation.
• 9:32
  SPEAKER_00: In one study of the triggerfish sensor, 82.5% of patients experienced transient blurred vision, and 80.0% had some redness during wear.
• 9:42
  SPEAKER_00: These effects were attributed to the lens prescription and corneal molding, and most were mild, measured by a tolerability visual analog scale of only 25100.
• 9:53
  SPEAKER_00: No serious harms were reported, but not all patients tolerate the lens.
• 9:57
  SPEAKER_00: Trials often screen for severe dry eye or corneal issues first.
• 10:02
  SPEAKER_00: Overall, while home IOP monitoring increases patient effort, studies find it is feasible and well accepted.
• 10:09
  SPEAKER_00: Patients largely do not mind adding IOP checks if it means better care.
• 10:13
  SPEAKER_00: Researchers ensure quality by training, certification, and electronic logging of readings.
• 10:19
  SPEAKER_00: In the end, these trials will clarify how to balance the extra data with the extra work, aiming to improve outcomes without overburdening patients.
• 10:29
  SPEAKER_00: Conclusion.
• 10:30
  SPEAKER_00: Emerging clinical trials around April 2026 are pioneering the use of home tenometers and contact lens pressure sensors in glaucoma care.
• 10:38
  SPEAKER_00: These protocols detail the devices from eye care home rebound tenometers to Sensymed trigger fish lenses, rigorous patient training and certification, and adherence support, like smartphone reminders.
• 10:51
  SPEAKER_00: They explicitly incorporate home IOP data into trial endpoints for efficacy and into action thresholds for safety.
• 10:59
  SPEAKER_00: As patients measure more IOP readings outside the clinic, the trials also address data quality checks and patient burden.
• 11:07
  SPEAKER_00: All evidence so far suggests that motivated patients can effectively use these tools, and that continuous monitoring may reveal pressure peaks missed in the office.
• 11:17
  SPEAKER_00: By 2026, home monitoring trials will help determine how best to integrate these novel sensors into routine glaucoma management, enhancing patient engagement and potentially improving disease control.
• 11:30
  SPEAKER_00: All links to sources are available in the text version of this article.
• 11:34
  SPEAKER_00: You can find the full article at VisualFieldTest.com.
• 11:38
  SPEAKER_00: Thanks for listening.
• 11:39
  SPEAKER_00: To check your visual field, click the link at the bottom of this article or visit visualfieldtest.com.